Monkeypox

To the Editor: Gessain et al. (Nov. 10 issue)(1) provide an important, comprehensive, and well-organized review of monkeypox (recently renamed mpox). Although the article states that the LC16m8 vaccine (KM Biologics) is not currently authorized for the prevention of mpox, it was approved against mpox for all ages, including children in high-risk groups, on August 1, 2022, in Japan.(2) As compared with the MVA-BN vaccine (Bavarian Nordic), the distinguishing features of LC16m8 is that it is a single-dose, highly attenuated but minimally replicating vaccine and that it has been approved for use in children. Even though the vaccine is replicating, . . .